Hangzhou Phecdamed Co., Ltd.
Clinical trials sponsored by Hangzhou Phecdamed Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to restore strength in aging muscles Results expected Aug 2027 (estimated)
-
New pill TJ0113 hopes to lift depression in 8 weeks
Symptom relief CompletedThis phase 2 trial tests an experimental drug called TJ0113 for people with depression. About 150 adults aged 18 to 65 will take either 200 mg or 400 mg of TJ0113 or a placebo daily for 8 weeks. Researchers will measure changes in depression symptoms using a standard rating scale…
Phase 2 • Sponsor: Hangzhou PhecdaMed Co., Ltd. • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
New drug TJ0113 tested in healthy people for first time
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of TJ0113 capsules in 130 healthy adults. Participants received either single or multiple doses of the drug or a placebo, and some took it after a high-fat meal. The study measured side effects and how the drug moves throu…
Phase 1 • Sponsor: Hangzhou PhecdaMed Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Drug tracking study in healthy men completed
Knowledge-focused CompletedThis study looked at how a drug called TJ0113 is processed and removed from the body in healthy Chinese men. Six participants took a single dose, and researchers measured the drug in their blood, urine, and stool over time. The goal was to understand how the drug is eliminated, n…
Phase 1 • Sponsor: Hangzhou PhecdaMed Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC